BCAL Diagnostics (ASX:BDX) Short-Term Debt : A$0.36 Mil (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is BCAL Diagnostics Short-Term Debt?

BCAL Diagnostics's Short-Term Debt for the quarter that ended in Dec. 2023 was A$0.36 Mil.

BCAL Diagnostics's quarterly Short-Term Debt stayed the same from Dec. 2022 (A$0.00 Mil) to Jun. 2023 (A$0.00 Mil) but then increased from Jun. 2023 (A$0.00 Mil) to Dec. 2023 (A$0.36 Mil).

BCAL Diagnostics Short-Term Debt Historical Data

The historical data trend for BCAL Diagnostics's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BCAL Diagnostics Short-Term Debt Chart

BCAL Diagnostics Annual Data

Trend

Jun22

Jun23

Short-Term Debt

BCAL Diagnostics Semi-Annual Data
	Dec20	Dec21	Jun22	Dec22	Jun23	Dec23
Short-Term Debt	Get a 7-Day Free Trial			-	-	-	-	0.36

BCAL Diagnostics Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

BCAL Diagnostics Short-Term Debt Related Terms

Thank you for viewing the detailed overview of BCAL Diagnostics's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

BCAL Diagnostics (ASX:BDX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » BCAL Diagnostics Ltd (ASX:BDX) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

Queen Victoria Building, GPO Box Q128, Sydney, NSW, AUS, 1230

Website

https://www.bcaldiagnostics.com

BCAL Diagnostics Ltd is a biotechnology company developing a novel blood screening test to improve the early diagnosis and monitoring of breast cancer by identifying, measuring, and validating specific biomarkers enriched from patient's blood. The BCAL technology utilizes a single blood test on multiple levels including disease detection, diagnostic mass screening, and post-intervention.